-- Sukumar Nagendran, Director, President, and Head of R&D, on April 10, 2026, sold 200,000 shares in Taysha Gene Therapies (TSHA) for $892,000. Following the Form 4 filing with the SEC, Nagendran has control over a total of 1,136,410 common shares of the company, with 1,136,410 shares held directly.
SEC Filing: